Structural Formula (Spl Image1 Structure)
Donepezil Hydrochloride
Product Images NDC 63629-1118
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 63629-1118). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 9 (Spl Image10 Figure9)
This is a table presenting the mean values and standard errors (SE) for the ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living) for two treatments: Donepezil Hydrochloride 10 mg/day and placebo. The table also shows the time of drug treatment which is 3 months and the 2 types of clinical change (improvement and decline).*
Figure 10 (Spl Image11 Figure10)
Figure 11 (Spl Image12 Figure11)
This is a report on the change from baseline of a drug called Donepezil Hydrochloride. The dosage was changed from 23mg to 10mg per day. The report also mentions a clinical improvement of 57% after weeks of drug treatment.*
Figure 12 (Spl Image13 Figure12)
This is a chart showing the cumulative percentage of patients who have taken either 23mg/day or 10mg/day of Donepezil HCI. The chart also shows a change from the baseline. The text includes some errors with non-English characters.*
Figure 13 (Spl Image14 Figure13)
Principal Display Panel – 23 mg Bottle Label (Spl Image15 Label)
The text describes medication called "Donepezil Hydrochloride" contained in a 90 tablet pack. It is a prescription-only medication that contains 23 mg of USP. The medicine should be kept out of the reach of children and stored in a tight and light-resistant container at a controlled room temperature. The NDC code for this medication pack is 63629-1118-1.*
Figure 1 (Spl Image2 Figure1)
Figure 2 (Spl Image3 Figure2)
Figure 3 (Spl Image4 Figure3)
Figure 4 (Spl Image5 Figure4)
This appears to be a graph depicting change in ADAS-cog scores over the course of 15 weeks of drug treatment. The drugs tested were Donepezil Hydrochloride at doses of 10 mg/day and 5 mg/day, compared to placebo. The graph shows an improvement in ADAS-cog scores for the 10 mg/day dose of Donepezil Hydrochloride and a decline in ADAS-cog scores for the placebo group. There is no available data for the 5 mg/day dose.*
Figure 5 (Spl Image6 Figure5)
The text represents a chart displaying the changes in ADAS-cop (Alzheimer's Disease Assessment Scale-cognitive subscale) for patients on different treatments. The chart shows the cumulative percentage of patients on placebo, 5mg/day of an unknown treatment, 10mg/day of the same treatment, and 20mg/day of a different treatment. The x-axis shows the change from baseline in the ADAS-cop score, and the y-axis shows the cumulative percentage of patients at each level of change. However, the values for the changes in ADAS-cop are not provided, making it difficult to interpret the chart accurately.*
Figure 6 (Spl Image7 Figure6)
This text appears to be a table or a graph showing the effectiveness of different medications, including Donepezil Hydrochloride and Placebo, in improving the condition of patients. The table also indicates the percentage of patients who have experienced marked, moderate, and minimal improvement, or no change or worsening of symptoms. Without any additional information or context, it is difficult to determine the exact purpose or implications of this information.*
Figure 7 (Spl Image8 Figure7)
Figure 8 (Spl Image9 Figure8)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
